MI HB4071

Requires health insurance policies to ensure that financial requirements for orally administered cancer medications are no more restrictive than those for intravenously administered or injected cancer medications.

Caps out-of-pocket costs (copay or coinsurance) for orally administered cancer medications at $250 per 30-day supply, with annual adjustments beginning January 1, 2026 based on the prescription drug index.

Prohibits insurers from complying with this requirement by increasing overall cost-sharing, reclassifying benefits, or imposing stricter treatment limitations on any cancer medications.

Permits insurers to continue using utilization management techniques such as prior authorization, step therapy, quantity limits, and days' supply restrictions.

Applies to health insurance policies delivered, issued, or renewed in Michigan after December 31, 2025, and became effective upon the 91st day after final adjournment of the 2023 Regular Session (approved October 24, 2023).